Probability of No Urgent Repeated Percutaneous Revascularization Procedures in the Three Treatment Groups (Kaplan-Meier Plots) Figure 1. Probability of.

Slides:



Advertisements
Similar presentations
Rabih R. Azar, MD, MSc, FACC Director of Cardiovascular Research Hotel Dieu de France Hospital Associate Professor of Medicine Saint Joseph University.
Advertisements

ARCTIC investigators COI D ISCLOSURE FOR D R. M ONTALESCOT : Research Grants to the Institution or Consulting/Lecture Fees from Abbott Vascular, Astra-Zeneca,
Stone p2203/Abstract/ Conclusions
Update on the Medical Management of Acute Coronary Syndrome.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Intravenous GP IIb/IIIa Inhibitors Abciximab (c7E3 Fab, ReoPro) = Human- murine chimeric monoclonal Fab antibody fragment Eptifibatide (Integrilin) =
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis Dr. Quan, Dr. Mirhashemi, Dr. Chiang N Engl J Med 2006; 355:
USE OF CITRATED CLOTTING TIME IN MONITORING ENOXAPARIN LEVEL DURING CONTEMPORARY PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROMES B.Y.C.
TIMI 11A A Multicenter Trial of the Safety and Tolerability of Two Doses of Enoxaparin in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Initiating Antiplatelet Therapy in Patients with Atherothrombosis
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
ISAR REACT 3 A. Kastrati, F.-J. Neumann, J. Mehilli, S. Schulz, G. Richardt, R. Iijima, R.A. Byrne, P.B. Berger, A. Schömig Bivalirudin Versus Unfractionated.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.
LBCT March 29, 08 ISAR REACT 3 A. Kastrati, F.-J. Neumann, J. Mehilli, S. Schulz, G. Richardt, R. Iijima, R.A. Byrne, P.B. Berger, A. Schömig Bivalirudin.
PRODIGY Objective Study Design Primary Composite Endpoint
THE MEDICINES COMPANY ® ® N = 9000 SA/NSTEMI/STEMI Maintenance Plavix PCI PLATFORM Screening Cangrelor infusion Placebo infusion PlavixPlacebo Plavix PCI.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
NSTE Acute Coronary Syndromes
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
CAPTURE: C 7E3 Fab A nti- P latelet T herapy in U nstable RE fractory Angina ¤ Study Population:Patients with chest pain at rest and ECG signs of UA (NQMI.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Dr. Quan, Dr. Mirhashemi, Dr. Chiang
The American College of Cardiology Presented by Dr. Adnan Kastrati
Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
For the HORIZONS-AMI Investigators
Women, Bleeding, and Coronary Intervention
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
Antiplatelet Therapy For STEMI: The Case for Cangrelor
ClinicalTrials.gov Identifier NCT
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
Late Breaking Clinical Trials
ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Section D: Clinical trial update: GP IIb/IIIa inhibition
EPIC: Balloon Angioplasty
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
% Heparin + GPI IIb/IIIa Bivalirudin +
These slides highlight a report on presentations at the Late-breaking Clinical Trials Session and a Satellite Symposium at the 53rd Annual Scientific.
American Heart Association Presented by Dr. Julinda Mehilli
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
In STEMI Complete Reperfusion (TFG 3, TMPG 3, ST Res  70%) is Associated with a Greater Percent of Receptors Occupied by Integrilin 52.0% % Pts With Complete.
Erasmus MC, Thoraxcenter
52.0% Complete Resolution TFG 3 TMPG 3 ST Resolution  70% p=0.006
Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.
(p = 0.32 for noninferiority)
Implications of Preoperative Thienopyridine Use
C-2. Clinical trial updates: Direct thrombin inhibitors
Svend A. Mortensen et al. JCHF 2014;2:
EPILOG Results: Balloon Angioplasty/Bail-out Stenting
Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Ron J.G. Peters,
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
IMPACT II Results: Balloon Angioplasty/Bail-out Stenting
European Heart Journal Advance Access
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test
Section C: Clinical trial update: Oral antiplatelet therapy
Presentation transcript:

Probability of No Urgent Repeated Percutaneous Revascularization Procedures in the Three Treatment Groups (Kaplan-Meier Plots) Figure 1. Probability of No Urgent Repeated Percutaneous Revascularization Procedures in the Three Treatment Groups (Kaplan-Meier Plots). Events began to occur shortly after the index procedure in the placebo group, between 6 and 12 hours after the procedure in the group given the bolus of c7E3 Fab, and even later in the group given both the bolus and the infusion. The y axis is truncated at 97 percent to demonstrate the differences in this end point, which occurred with low frequency. Accessed from: The EPIC Investigators. N Engl J Med 1994;330:956-961

EPIC: Risk of Bleeding with Placebo, Bolus, and Bolus and Infusion Variable Placebo (n=696) C7E3Fab Bolus (n=695) c7E3 Fab Bolus + Infusion (n=708) Major Bleeding – no. (%) 46 (7) 76 (11) 99 (14) Site of Major Bleeding – no. (%) Groin 20 49 58 Need for Surgical Repair 7 (1.0) 16 (2.3) 6 (0.8) Retroperitoneal 3 12 Coronary Artery 23 21 26 Intracranial 2 1 Hematemesis 5 11 Transfusions -- no. (%) Red cells 49 (7) 92 (13) 109 (15) Platelets 18 (3) 29 (4) 39 (6) Accessed from: The EPIC Investigators. N Engl J Med 1994;330:956-961

Reanalysis of EPIC: Early outcomes: Composite rate of death, MI, urgent intervention Time endpoint assessed postrandomization Placebo Bolus P Bolus+ Infusion p vs placebo 6 hour 5.3% 2.9% 0.22 2.4% 0.005 12 hour 6.7% 4.7% 0.129 4.2% 0.047 Marmur JD et al. Am Heart J 2006

EPIC: Heparin Dosing was High Heparin was given intravenously in an initial bolus dose of 10,000 to 12,000 units followed by incremental bolus doses of up to 3000 units at 15-minute intervals, but no more than 20,000 units was given during the procedure; the goal was to keep the activated clotting time between 300 and 350 seconds during the operation. Heparin was continued by constant infusion for at least 12 hours to maintain the activated partial-thromboplastin time at 1.5 to 2.5 times the control value. The EPIC Investigators. N Engl J Med 1994;330:956-961

Limitations of EPIC in the Assessment of Bolus Vs Infusion High doses of heparin cloud assessment of safety Late events after 24 hours in the era of conventional balloon angioplasty may be abrupt closure which has been reduced with the use of stents Clopidogrel loading was not practiced in EPIC Placebo arm in EPIC was UFH and not Enox or Bival Gibson CM, 2006